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Abstract
Background: The aim of the present study is to determine the variables affecting blood glucose concentrations
outside the target range of 80 and 150 mg/dl in critically ill surgical patients.
Methods: All critically ill surgical patients admitted to a university ICU, from 01/2007 to 12/2008, were surveyed
daily using computer assistance with respect to minimal and maximal daily blood glucose concentrations,
application of insulin and demographic/clinical variables. Multiple logistic regression for clustered data with
backward elimination was performed to identify variables strongly associated with blood glucose concentrations
< 80 mg/dl or ≥ 150 mg/dl in 804 patients with an ICU stay > 72 hours.
Results: Application of insulin (odds ratio (OR) 2.1, with corresponding 95% confidence interval (CI) 1.7; 2.6),
noradrenaline (OR 1.4, 95% CI 1.2 - 1.8) or steroids (1.3, 1.003 - 1.7), and age (per year) (1.02, 1.01 - 1.03) were
associated with an increased risk of blood glucose concentrations < 80 mg/dl. In analogy, application of insulin
(OR 2.4, 95% CI 2.0 - 2.7), noradrenaline (1.4, 1.2 - 1.6) or steroids (1.4, 1.2 - 1.7), severe sepsis (1.2, 1.1 - 1.4),
neurosurgery (OR 1.0) compared to abdominal, vascular and trauma surgery, and age (per year) (1.01, 1.01 - 1.02),
were associated with an increased risk of blood glucose concentrations ≥ 150 mg/dl.
Conclusions: Critically ill surgical patients are at an increased risk for fluctuating blood glucose concentrations
ranging < 80 mg/dl or ≥ 150 mg/dl in particular if they are of advanced age and require administration of insulin,
noradrenaline, and/or steroids. Patients who underwent neurosurgery and/or presented with severe sepsis/shock
are those in particular at risk for blood glucose concentrations ≥ 150 mg/dl.
Background
In 2004 and 2008, the “Surviving Sepsis Campaign”
(SSC) guidelines for the management of severe sepsis
and septic shock were published to improve outcome of
critically ill patients [1,2]. These guidelines recommend
that patients with severe sepsis/septic shock and blood
glucose concentrations ≥ 150 mg/dl receive IV insulin
therapy to keep blood glucose levels in the range of 80 -
150 mg/dl [1,2]. A validated protocol for insulin dose
adjustments was suggested targeting glucose levels of
< 150 mg/dl [1,2].
Prophylactic perioperative intensive insulin therapy
(IIT) reduced mortality and organ dysfunctions [3] in
surgical patients, with a length of stay in the intensive
care unit (ICU) of at least three days [4], but not in a
combined population of medical/surgical patients [5],
nor in patients with severe sepsis [6]. In contrast to the
first two successful trials [3,4], five randomized con-
trolled trials showed no beneficial effects of strict glyce-
mic control with intensive insulin therapy [5-8]. Some
reasons for these contrasting observations are due to
variability in the performance of strict glycemic control,
differences among trial designs, changes in standard of
care, time initiation of strict glycemic control, and the
convergence between the intervention groups and con-
trol groups with respect to achieved blood glucose levels
in the successive randomized controlled trials [7]. Large
variability of blood glucose concentrations in IIT and
control groups was considered as one possible explana-
tion for the lack of beneficial effects of insulin therapy
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[9,10]. Moreover, patients with sepsis and increased gly-
cemic lability index, but lower average glucose values,
had an almost five-fold increased risk of hospital mortal-
ity (odds ratio = 4.73, 95% confidence interval = 2.6 - 8.7)
[11]. It remained unclear whether the increased suscept-
ibility to severe hypoglycemia (glucose level ≤ 40 mg/dl)
with intensive insulin therapy in sepsis patients was due
to liver and renal dysfunction [6]. Taken together, recog-
nizing predisposing factors for blood glucose con-
centrations < 80 mg/dl or ≥ 150 mg/dl might help in
identifying patients at risk so that more intensive moni-
toring or less tight blood glucose targets could be used.
In this context, the following variables have been
reported to be associated with increased risk for hypo-
glycemia or hyperglycemia: age [12,13], sex [12], type of
surgery; severity of disease [14] and severe systemic
inflammatory response syndrome (SIRS)/sepsis [15,16];
kidney [14,17], liver [17] and organ dysfunctions; appli-
cation of steroids [13,18-21], adrenaline and/or noradre-
naline infusion [16,21,22]. Nonetheless, it was unclear
which of these factors are most responsible in hindering
the efforts to maintain blood glucose levels in the range
of 80 - 150 mg/dl as adviced by the SSC guidelines
[1,2]. Therefore, the present study was performed in a
surgical adult intensive care unit (ICU) in surgical criti-
cally ill patients with an ICU stay > 72 hours to answer
the following questions:
1. What is the frequency of observed blood glucose
levels outside the target range of 80 - 150 mg/dl?
2. Is age, gender, type of surgery, severity of disease,
severity of organ dysfunctions, application of steroids,
adrenaline, noradrenaline, steroids or insulin, and severe
sepsis and shock associated with blood glucose concen-
trations < 80 mg/dl or ≥ 150 mg/dl, respectively?
3. What factors are most responsible for blood glucose
levels outside the target range?
Methods
Patients and data collection
The prospective study is in compliance with the Helsinki
declaration and was approved by the Independent Ethics
Committee of the University Ulm, which waived
informed consent because this was an observational
study, and no additional interventions were performed.
All surgical critically ill patients, from 01/2007 to
12/2008, admitted to the Anesthesiology ICU of the Uni-
versity Hospital Ulm after major trauma, vascular, lung,
brain and abdominal surgery were followed daily, compu-
ter assisted, for minimal and maximal blood glucose
concentrations.
The following variables were documented on admission:
age, sex, type of surgery (major trauma, vascular and lung,
brain or abdominal surgery), and severity of disease by the
Simplified Acute Physiology Score II (SAPS II) score [23].
The severity of the systemic inflammatory response
syndrome (SIRS)/sepsis and shock (the 1992 American
College of Chest Physicians/Society of Critical Care Medi-
cine (ACCP/SCCM) consensus conference definitions [24]
and the 2003 SCCM/ESICM/ACCP/ATS/SIS sepsis defi-
nitions [15]), acute kidney injury demanding extracorpor-
eal renal support, liver dysfunction assessed by the Model
of Endstage Liver Disease (MELD) score [25], organ
dysfunctions reflected by the Sequential Organ Failure
Assessement (SOFA) score [26], insulin administration,
steroid, adrenaline and/or noradrenaline infusion, were
monitored, computer-assisted, on a daily basis by the ICU
residents and staff physicians. SIRS was defined by two or
more of the four conditions: temperature, heart rate,
respiratory rate, and white blood cell count (WBC) by the
1992 definitions. If SIRS was due to a documented infec-
tion, patients were classified as sepsis patients. Severe
sepsis was defined as sepsis accompanied by organ dys-
function, i. e., defined as recommended [26] for the 1992
sepsis definitions, or greater than two points in one organ
system using the SOFA score. Septic shock was defined as
sepsis together with hypotension despite adequate fluid
resuscitation. Sepsis was defined due to the 2003 defini-
tions [15], if at least two out of the enlarged list of general
and inflammatory variables were fulfilled, i.e., temperature,
heart rate, respiratory rate, significant edema, positive fluid
balance, hyperglycemia (plasma glucose > 120 mg/dl),
white blood cell count (WBC), and plasma C-reactive pro-
tein. Severe sepsis was defined as sepsis plus organ
dysfunction according to the limitations for organ
dysfunction variables and tissue perfusion variables (hyper-
lactatemia) given in the 2003 sepsis definitions publication
[15]. The reason for the two sepsis definitions is that the
frequency and mortality rates of various sepsis severity
stages differ if defined by the 1992 or the 2003 definitions
within the same patient population [27]. The 1992 defini-
tions may under-classify patients with severe sepsis. Thus,
transferring recommendations such as those of the SSC
guidelines drawn from data sets regarding severity of sep-
sis generated with the 1992 definitions to the same popu-
lation applying the 2003 definitions may be misleading.
Therefore, in the present study, sepsis was defined using
the original 1992 ACCP/SCCM [24] and the revised 2003
SCCM/ESICM/ACCP/ATS/SIS sepsis definitions [15]. In
the 2003 definitions, hyperglycemia is defined as plasma
glucose > 120 mg/dl in the absence of diabetes and is one
of the general variables in the diagnostic criteria for sepsis.
Therefore, we expected different subgroups of patients in
our patient collective when defining sepsis with the 1992
or the 2003 definitions. Acute kidney injury was defined as
urine output < 0.5 ml/kg for more than 2 hours [15], and/
or increase in creatinine > 44 umol/l [15] and/or extracor-
poreal renal support [15]. Hydrocortisone was used
in adult septic shock according to the SSC guidelines [1,2],
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i. e., after blood pressure was identified to be poorly
responsive to fluid resuscitation and vasopressor therapy.
The following patients were excluded in the final eva-
luation: patients with unfavorable prognosis, patients
< 18 years (because SAPS II score [23] and the ACCP/
SCCM sepsis definitions [24] have been developed for
patients ≥ 18 years, and the SOFA score [26] for
patients ≥ 12 years), patients with insulin dependent dia-
betes mellitus, patients with previous diagnosis of dia-
betes mellitus, and patients with a stay < 72 hours on
the ICU in analogy to previous studies [4].
Routine blood glucose measurements were performed
by a blood gas analyzer (Radiometer Copenhagen
GmbH, Willich, Germany) according to the guidelines
of the “Surviving Sepsis Campaign” [1,2]. Thus, in our
department, glucose measurements are performed routi-
nely every 1 - 2 hrs (4 hrs when stable) in patients
receiving intravenous insulin, and every 30 to 60 min-
utes in patients with glucose values < 80 mg/dl. In
severely ill patients without insulin administration,
blood glucose was measured at least four times a day.
Statistical analysis
Data comprised clustered observations because of
repeated measures taken during each patient’s course in
the ICU. Therefore, analyses of associations between
blood glucose concentrations < 80 mg/dl/blood glucose
concentrations ≥ 150 mg/dl and demographic/clinical
variables were performed in a logistic regression
adjusted for clustered observations.
In a first step, separately for each of the two outcome
variables (blood glucose concentrations < 80 mg/dl vs
80 - < 150 mg/dl, and blood glucose concentrations
≥ 150 mg/dl vs 80 - < 150 mg/dl) and any of the explana-
tory variables, associations were assessed by logistic
regression. Crude odd ratios (ORs) with 95% confidence
interval (CI) and p-values were calculated.
In a second step, for each outcome variable, the expla-
natory variables were assessed simultaneously, and rele-
vant factors were identified by backward elimination in
a multiple logistic regression.
Results
During the period dating from 01/2007 to 12/2008, 1637
postoperative/posttraumatic critically ill patients were
admitted to the ICU. A total of 804 patients met the
inclusion criteria with an ICU stay > 72 hours and were
eligible for final evaluation.
Baseline characteristics of these patients were as fol-
lows. The median of age was 65 (range 18 - 98, mean
61.0, SD 17.1). Out of these 804 patients, 241 (30%)
were female, 84 (10.5%) were non-survivors, 225 (28%)
were admitted due to neurosurgery, 217 (27%) due to
abdominal surgery, 193 (24%) due to vascular surgery,
and 169 (21%) due to trauma surgery. The median
SAPS II score on admission was 32 (range 6 - 82, mean
34.5, SD 15.9).
Characteristics during the course on the ICU were as
follows. Insulin was applied in 642 (79.9%) of the 804
patients, steroids in 265 (33.0%), adrenaline in 191 (23.8%),
noradrenaline in 564 (70.2%). Extracorporeal renal support
was performed in 84 (10.5%) patients. 478 (60.0%) patients
had severe SIRS/sepsis due to the 1992 definitions, and
705 (88.7%) due to the 2003 definitions. The maximal
MELD score was 7 in median (range -46 - 69, mean 9.6,
SD 9.98). The maximal SOFA score was 6 in median
(range 0 - 18, mean 6.5, SD 3.3).
Complete information regarding the daily minimal and
maximal blood glucose concentrations, insulin administra-
tion, demographic/clinical variables and scores were avail-
able in 7409 observations in total, of these 2273 without
and 5136 with insulin administration. The number of
observations within distinct blood glucose ranges in all
patients are presented in Table 1. Blood glucose concen-
trations < 80 mg/dl occured in 10.9% of our observations.
To identify variables strongly associated with blood glu-
cose concentrations < 80 mg/dl or ≥ 150 mg/dl, crude
odds ratios (OR) with 95% confidence intervals (95% CI)
and p-values were calculated and are presented in Table 2.
The variables associated with an increased risk of blood
glucose concentrations < 80 mg/dl were: age, female sex,
SAPS II > 36, MELD > 9, SOFA > 4, application of adrena-
line, noradrenaline, steroids or insulin. Those variables
associated with an increased risk of blood glucose concen-
trations ≥ 150 mg/dl were: age, neurosurgery compared to
all other types (abdominal, vascular, trauma surgery),
SAPS II > 36, sepsis defined by the 1992 or the 2003
definitions, MELD > 9, SOFA > 4, and administration of
adrenaline, noradrenaline, steroids or insulin.
Multiple logistic regression with backward elimination
was performed to simultaneously assess and identify vari-
ables strongly associated with blood glucose concentra-
tions < 80 mg/dl or ≥ 150 mg/dl. Thereby, increasing age,
application of noradrenaline, steroids or insulin were
strongly associated with blood glucose concentrations
< 80 mg/dl (Table 3). In addition to these variables,
Table 1 Distribution of the number of observations
within various blood glucose ranges
Observations (all, n = 7,409)
Blood glucose (mg/dl) % of all
< 40 65 0.9%
40 to <60 122 1.6%
60 to <80 623 8.4%
80 to <150 3583 48.4%
≥ 150 3016 40.7%
To convert the values for glucose to millimoles per litre, multiply by 0.05551.
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neurosurgery compared to all other types of surgery, and
sepsis as defined by the 1992 definitions were strongly
associated with blood glucose concentrations ≥ 150 mg/dl
(Table 3).
The relationship of clinical outcome and blood glu-
cose concentrations < 80 mg/dl or ≥ 150 mg/dl is given
in Table 4. Compared to patients with blood glucose
levels always within the target range of 80 to 150 mg/dl,
patients with episodes of blood glucose concentrations
< 80 mg/dl, ≥ 150 mg/dl, as well as < 80 mg/dl and ≥
150 mg/dl, in addition, revealed an increased risk of
death (p = 0.009).
Discussion
The present study reveals that the most relevant factors
associated with blood glucose concentrations < 80 mg/
dl or ≥ 150 mg/dl are age and application of noradrena-
line, steroids or insulin. In addition, neurosurgery and
severe sepsis/shock are variables strongly associated
with blood glucose concentrations ≥ 150 mg/dl.
Patients who underwent neurosurgery and those in
septic shock [1,2], are frequently treated with noradrena-
line and steroids. In separate analyses of explanatory vari-
ables (Table 2), severe sepsis/septic shock was associated
with increased risk of blood glucose concentrations
≥ 150 mg/dl. Hyperglycemia, i. e. plasma glucose >
120 mg/dl in the absence of diabetes, is one of the broa-
dened diagnostic criteria for sepsis in the 2003 definition.
The frequencies of severe sepsis and septic shock were
higher and mortality rates lower when the 2003 defini-
tions (lower thresholds for the definition of organ
dysfunctions [15]) were applied instead of the 1992 defi-
nitions although it was in the same population of criti-
cally ill surgical patients [27]. Elderly neurosurgical
patients requiring noradrenaline to increase intracranial
perfusion pressure and steroids to reduce edema and
swelling, as well as elderly patients with more severe
organ dysfunctions and in septic shock who were treated
with noradrenaline and steroids according to the “Surviv-
ing Sepsis Campaign” guidelines [1,2] are at higher risk
for blood glucose concentrations ≥ 150 mg/dl.
In a recent meta-analysis, there was no survival benefit
regarding tight glucose control with intensive insulin
therapy (IIT) in all analyzed 13,567 patients (OR 0.93,
95% CI 0.83 - 1.04), however, in the subset of surgical
patients (OR 0.63, 95% CI 0.44 - 0.90) [8] there was a
significant survival benefit. In the perioperative concept
of IIT, the greatest reduction in mortality in surgical ICU
patients with sepsis and receiving mechanical ventilation
involved deaths due to multiple-organ failure [3]. In
these patients with severe sepsis it was speculated that
the higher rate of severe hypoglycemia in the IIT group
[3] was due to renal or liver dysfunction [6]. In the pre-
sent study, surgical patients with renal dysfunction
assessed as extracorporeal renal replacement therapy
were not associated with an increased risk of blood glucose
concentrations < 80 mg/dl or ≥ 150 mg/dl (Table 2, 3).
This is in contrast to medical-surgical ICU patients, where
Table 2 Crude OR (95% CI) of factors associated with blood glucose concentrations < 80 mg/dl or ≥ 150 mg/dl
BG < 80 vs 80 ≤ BG < 150 BG ≥150 vs 80 ≤ BG <150
OR (95% CI) P value OR (95% CI) P value
Age (per year) 1.02 (1.01; 1.03) <0.001 1.02 (1.01; 1.02) <0.001
Gender (female vs male) 1.4 (1.1; 1.8) 0.014 1.1 (0.95; 1.4) 0.148
Neurosurgery 1.0 0.324 1.0 <0.001
Abdominal surgery 0.8 (0.6; 1.1) 0.7 (0.6; 0.9)
Vascular surgery 0.8 (0.6; 1.1) 0.7 (0.6; 0.9)
Trauma surgery 0.7 (0.5; 1.03) 0.5 (0.4; 0.7)
SAPS II (>36 vs ≤36) 1.5 (1.2; 1.8) <0.001 1.5 (1.3; 1.7) <0.001
Sepsis 1992 severe/shock (yes vs no) 1.2 (0.99; 1.4) 0.068 1.4 (1.2; 1.6) <0.001
Sepsis 2003 severe/shock (yes vs no) 1.1 (0.9; 1.3) 0.355 1.2 (1.04; 1.3) 0.012
Extracorporeal renal replacement therapy (yes vs no) 1.3 (0.9; 1.8) 0.124 1.3 (0.95; 1.7) 0.103
MELD (>9 vs ≤9) 1.3 (1.1; 1.7) 0.008 1.3 (1.1; 1.5) 0.005
SOFA (>4 vs ≤4) 1.4 (1.2; 1.7) <0.001 1.5 (1.3; 1.7) <0.001
Adrenaline (yes vs no) 1.7 (1.9; 2.4) 0.004 1.3 (1.02; 1.6) 0.031
Noradrenaline (yes vs no) 1.7 (1.4; 2.0) <0.001 1.7 (1.5; 2.0) <0.001
Steroids (yes vs no) 1.8 (1.4; 2.2) <0.001 2.0 (1.7: 2.3) <0.001
Insulin (yes vs no) 2.4 (1.9; 3.0) <0.001 2.8 (2.4; 3.2) <0.001
BG = blood glucose; CI = confidence interval; IIT = intensive insulin therapy; MELD = model of end stage liver disease; OR = odds ratio; SAPS II = Simplified Acute
Physiology Score; SOFA = Sequential Organ Failure Assessment.
Number of data sets: see Table 1. ORs with p < 0.05 are highlighted in bold numbers.
To convert the values for glucose to millimoles per litre, multiply by 0.05551.
For comparison with the other types of surgery, the risk has been set at 1 for neurosurgery.
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hemodialysis was a predictor of hypoglygemia [10] and
renal insufficiency was an independent risk factor for
severe hypoglycemia [14]. In the present study, severity of
liver dysfunction was assessed by the MELD score and of
organ dysfunctions by the SOFA score. In separate analyses
(Table 2), a MELD score > 9 and a SOFA score > 4 were
associated with a higher risk of blood glucose concentra-
tions < 80 mg/dl or ≥ 150 mg/dl, however, this association
was not found by multiple logistic regression (Table 3). In
medical-surgical ICU patients, female gender was one of
the main predictors of hypoglycemia [10]. The higher risk
of blood glucose concentrations < 80 mg/dl with age
(Tables 2, 3) and female gender (Table 2) in the present
study are most probably due to an impaired counterregula-
tory response [12]. The higher risk of hypoglycemia may
be due to the lower counterregulatory hormone threshold
for hypoglycemia in women than in men, i. e., especially
adrenaline, noradrenaline and growth hormone response
[12]. The association of blood glucose concentrations
< 80 mg/dl with administration of noradrenaline and ster-
oids was surprising. In a rat model of continuous endo-
toxin infusion resembling some of the metabolic and
cardiovascular constellations of human sepsis, a decreased
number of hepatic plasma membrane alpha 1-adrenergic
receptors were found [28]. This might in part explain why
a comparable subset of our patients might not have devel-
oped blood glucose concentrations ≥ 150 mg/dl but < 80
mg/dl in association with continuous noradrenaline infu-
sion. On the other hand, hyperglycemia due to insulin
resistance has been reported in human sepsis. Adipokine
levels were extensively altered in patients with severe sepsis
and shock [29]. Adiponectin, the prototype of an anti-
inflammatory and insulin-sensitizing adipocytokine, was
diminished in these patients [29]. Out of the insulin-resis-
tance mediating factors, plasminogen activator inhibitor-1
(PAI-1), MCP-1, IL-6, IL-8, IL-10 and tumour necrosis
Table 3 Multiple logistic regression with backward elimination
BG < 80 vs 80 ≤ BG < 150 BG ≥ 150 vs 80 ≤ BG < 150
OR (95% CI) P value OR (95% CI) P value
Age (per year) 1.02 (1.01; 1.03) <0.001 1.01 (1.01; 1.02) <0.001
Gender (female vs male) – –
Neurosurgery – 1.0 <0.001
Abdominal surgery 0.6 (0.5; 0.7)
Vascular surgery 0.7 (0.6; 0.9)
Trauma surgery 0.6 (0.5; 0.8)
SAPS II (>36 vs ≤36) – –
Sepsis 1992 severe/shock (yes vs no) – 1.2 (1.1; 1.4) 0.003
Sepsis 2003 severe/shock (yes vs no) – –
Extracorporeal renal replacement therapy (yes vs no) – –
MELD (>9 vs ≤9) – –
SOFA (>4 vs ≤4) – –
Adrenaline (yes vs no) – –
Noradrenaline (yes vs no) 1.4 (1.2; 1.8) <0.001 1.4 (1.2; 1.6) <0.001
Steroids (yes vs no) 1.3 (1.003; 1.7) 0.047 1.4 (1.2; 1.7) <0.001
Insulin 2.1 (1.7; 2.6) <0.001 2.4 (2.0; 2.7) <0.001
OR (95% CI) of factors associated with blood glucose concentrations < 80 mg/dl or ≥ 150 mg/dl.
BG = blood glucose; CI = confidence interval; IIT = intensive insulin therapy; MELD = model of end stage liver disease; OR = odds ratio; SAPS II = Simplified Acute
Physiology Score; SOFA = Sequential Organ Failure Assessment.
Number of data sets: see Table 1.
To convert the values for glucose to millimoles per litre, multiply by 0.05551.
For comparison with the other types of surgery, the risk has been set at 1 for neurosurgery.
Table 4 Blood glucose variability and outcome
80 ≤ BG < 150 (mg/dl) Total patients Nonsurvivors (%) OR (95% CI) P value
always 118 4 (3.4%) 1.0 0.009
plus BG < 80 26 2 (7.7%) 2.4 (0.4; 13.7)
plus BG ≥ 150 450 45 (10.0%) 3.2 (1.1; 9.0)
plus BG < 80 and BG ≥ 150 210 33 (15.7%) 5.3 (1.8; 15.4)
804 84 (10.5%)
BG = blood glucose; CI = confidence interval.
To convert the values for glucose to millimoles per litre, multiply by 0.05551.
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factor (TNF)-a were significantly elevated in these patients.
All significant changes were shifted in the same direction
as in obese subjects and patients with type 2 diabetes.
These results may help to explain insulin resistance in criti-
cally ill patients and patients with systemic inflammatory
response syndrome. After diagnosis of severe sepsis and
shock, serum adiponectin levels and hydrocortisone corre-
lated positively with insulin demand, and noradrenaline
demand negatively with male adiponectin levels [30]. Septic
shock causes a massive dilation of the peripheral vascular
system, promoted by inflammatory cytokines and microbial
toxins. Thus, the dosages of noradrenaline needed to pro-
vide a sufficient mean arterial pressure can be used to
assess the degree of deterioration of the circulation
(Sequential Organ Failure Assessment, SOFA score) for
severity of organ dysfunction [26]. Thus, an increase in
noradrenaline demand may reflect a clinical situation with
changes in adipokines resulting in insulin resistance. Taken
together, these data in septic patients may explain why we
observed a positive association of noradrenaline with blood
glucose concentrations ≥ 150 mg/dl. On the other hand,
adipokine panels resulting in overwhelming insulin sensi-
tivity might set patients at risk of blood glucose concentra-
tions < 80 mg/dl. In this constellation, we might get an
association of steroid and noradrenaline treatment with
blood glucose concentrations < 80 mg/dl, which is not due
to the effects of steroids or noradrenaline per se. The vari-
ables SAPS II > 36, MELD > 9, and SOFA > 4 in the pre-
sent study were associated with an increased risk of blood
glucose concentrations < 80 mg/dl reflecting patients with
greater severity of disease and organ dysfunctions. One
third of our patients were neurosurgical patients. Neuro-
surgical patients are often treated with noradrenaline to
increase intracranial perfusion pressure and steroids to
reduce edema and swelling. Thus, the pathopysiological
reasons and the underlying adipokine pattern during ster-
oid or noradrenaline treatment in our heterogenous patient
groups may differ profoundly. This might explain why we
found noradrenaline and steroid treatment as risk factors
for both, blood glucose concentrations ≥ 150 mg/dl and
< 80 mg/dl.
The blunted ability of neutrophils to adapt to physio-
logical hyperinsulinemia in older people (69 +/- 4 years)
may compromise the anti-infective response [31], and
may contribute to sepsis. Taken together, elderly female
patients with extracorporeal renal replacement therapy
and/or liver dysfunction, especially under IIT, may be at
increased risk of hypoglycemia.
The “Surviving Sepsis Campaign” guidelines for the
management of severe sepsis and septic shock recom-
mended intensive insulin therapy (IIT) targeting of glu-
cose levels to the < 150 mg/dl range [1,2]. In the present
study, 48.4% of minimal and maximal blood glucose data
sets per day were in the target range of 80 to < 150 mg/dl
(Table 1). This is comparable with a previous study in a
mixed medical-surgical ICU with strict glycemic control,
in which less than 50% of patients were within the target
range with a considerable overlap between the intensive
and the standard insulin group [10]. In the present study,
severity of disease was assessed by SAPS II score. In sepa-
rate analysis only (Table 2), SAPS II was associated with
increased risk for blood glucose concentrations < 80 mg/
dl or ≥ 150 mg/dl, however, not in multiple logistic
regression (Table 3). Severity of illness reflected by the
APACHE II score was one of the factors associated with
the development of severe hypoglycemia in medical,
surgical, and cardiac ICU patients in multiple logistic
regression [10,14]. Thus, the severity of disease may
put patients at risk of not falling within the recom-
mended target range of 80 to 150 mg/dl blood glucose
concentration.
In the present study, the overall hypoglycemia rates
observed with blood glucose concentrations < 40 mg/dl
in 0.9% and < 80 mg/dl in 10.9% (Table 1) were low,
furthermore the administration of insulin was associated
with an increased risk of blood glucose concentrations
< 80 mg/dl (OR 2.1; 95% CI 1.7 - 2.6) (Table 3). A com-
parison with hypoglycemia rates in the literature is diffi-
cult since hypoglycemia rates with IIT might be related
to differences in patient populations, severity of illness,
protocols, blood glucose targets, definitions of hypoglyce-
mia, proportion of diabetic patients, ICU length of stay
or duration of therapy. For example, the rates of hypogly-
cemia (≤ 40 mg/dl) were 0.5% [5], 1.7% [32] and 2.7%
[33] in the control group, and 6.8% [5], 8.5% [32], 8.7%
[33] and 16% [10] in the IIT group, respectively, in mixed
surgical/medical ICUs. Taken together, in a recent meta-
analysis, IIT was associated with a high risk (OR 6.0, 95%
CI 4.5 - 8.5) for hypoglycemia < 40 mg/dl [8].
A comparison to patients with blood glucose levels
always within the target range of 80 to 150 mg/dl,
patients with episodes of blood glucose concentrations <
80 mg/dl, of ≥ 150 mg/dl, or of both, revealed an
increased risk of death (Table 4). It has been suggested
that quadrupling the rate of severe hypoglycemia and
doubling the mortality attributable to severe hypoglyce-
mia would erase the survival benefit of IIT in medical,
surgical, and cardiac patients [14]. It remains unclear,
whether hypoglycemia is associated with worse outcome
or is simply a marker of severity of illness [10]. Sponta-
neous hypoglycemia without insulin therapy might be
even more dangerous, resulting in a 1.7-fold increase in
mortality [34], because it is often detected late, further-
more, the duration of the episodes are longer due to less
frequent monitoring than with IIT.
Thus, it is of high clinical relevance to know that
beyond insulin therapy, the most relevant factors asso-
ciated with hypoglycemia were noradrenaline infusion,
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steroids and age (Table 3). To prevent deleterious hypo-
glycemia, a higher target range of 140 - 180 instead of
< 150 mg/dl in critically ill patients was recently sug-
gested [35,36].
The strengths of our study are that our ICU has a
high nursing staff to patient ratio and is operated 24/7
by an on-site Critical Care Board-certified intensivist,
and that intervention-related risk factors for blood glu-
cose concentrations ≥ 150 mg/dl were evaluated. On the
other hand, our study has several limitations. It is a sin-
gle center trial. Other factors include adherence to the
intensive insulin therapy protocol, the frequency of glu-
cose measurements, the amount of average calories/day,
the insulin dose, and the small number of hypoglycemic
episodes < 40 mg/dl, however most of the aforemen-
tioned limitations apply to many of the recently pub-
lished studies concerning IIT as well.
Conclusions
The present study shows that the most relevant factors
for blood glucose concentrations < 80 mg/dl in critically
ill surgical patients were age, administration of noradre-
naline, steroids and insulin. The most relevant factors
for blood glucose concentrations ≥ 150 mg/dl were age,
neurosurgery, severe sepsis/shock as defined by the 1992
definitions, steroids, noradrenaline and insulin. Thus,
physicians and nurses have to be alert to these factors
to avoid blood glucose concentrations < 80 mg/dl or
hypoglycemia induced harm, especially in subgroups of
patients with a combination of these most relevant
factors.
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